MedTech & Diagnostics
Merit Medical Systems Executive Compensation (FY25)
MMSI · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Martha Aronson | Median of the other named officers $4,440,299 5 officers, excluding the chief executive | Latest say-on-pay support = May 13, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Merit Medical Systems brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 20, 2026Latest filing (8-K): May 19, 2026
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
314 figures on this page: 303 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
CEO pay ratio: 290:1 → 184:1 (36.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Merit Medical Systems' chief executive and what were they paid?
Total compensation for Martha Aronson, President and Chief Executive Officer, came to $6,728,320 in fiscal 2025.
What was Merit Medical Systems' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 97.2% of votes cast for or against in favor at the meeting held May 13, 2026.
Which companies are in Merit Medical Systems' peer group?
The disclosed peer group names CONMED Corporation, Globus Medical, Inc., Haemonetics Corporation, ICU Medical, Inc. and Inspire Medical Systems, among others.
What is Merit Medical Systems' chief executive pay ratio?
The company reported a chief executive pay ratio of 184:1 for fiscal 2025, against median employee compensation of $40,694.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Fred Lampropoulos Chair of the Board, CEO and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ronald Frost Former Chief Operating Officer (10) Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Raul Parra Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Joseph Wright Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Brian Lloyd Chief Legal Officer, Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Neil Peterson Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Fred Lampropoulos Former Chair of the Board, CEO and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Raul Parra Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Neil Peterson Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Brian Lloyd Chief Legal Officer, Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Fred Lampropoulos Former Chair of the Board, CEO and President | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Joseph Wright Former President Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Raul Parra Chief Financial Officer and Treasurer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Neil Peterson Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Lloyd Chief Legal Officer, Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Fred Lampropoulos Former Chair of the Board, CEO and President Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Martha Aronson President and Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | — | ◇ |
Raul Parra Chief Financial Officer and Treasurer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Lloyd Chief Legal Officer and Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Neil Peterson Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michel Voigt Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Brian G. Lloyd | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Fred P. Lampropoulos | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Martha G. Aronson | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michel J. Voigt | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Neil W. Peterson | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Raul Parra | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Fred Lampropoulos | Option | ◇ | — | ◇ | 2/28/2030 |
| Option | ◇ | — | ◇ | 2/28/2029 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michel Voigt | Option | ◇ | — | ◇ | 2/28/2029 |
| Option | ◇ | — | ◇ | 2/28/2030 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Brian Lloyd | Option | ◇ | — | ◇ | 2/28/2030 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/28/2029 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Neil Peterson | Option | ◇ | — | ◇ | 2/28/2030 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Raul Parra | Option | ◇ | — | ◇ | 2/28/2030 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/28/2029 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Martha Aronson | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Brian Lloyd
Chief Legal Officer and Corporate Secretary · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Martha Aronson
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
Michel Voigt
Chief Human Resources Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Neil Peterson
Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
Raul Parra
Chief Financial Officer and Treasurer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
F. Ann Millner, Ed.D Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Lynne N. Ward | ◇ | ◇ | — | — | — | — | ◇ |
Lonny J. Carpenter | ◇ | ◇ | — | — | — | — | ◇ |
Thomas J. Gunderson | ◇ | ◇ | — | — | — | — | ◇ |
David K. Floyd | ◇ | ◇ | — | — | — | — | ◇ |
Stephen C. Evans | ◇ | ◇ | — | — | — | — | ◇ |
Silvia M. Perez | ◇ | ◇ | — | — | — | — | ◇ |
Laura S. Kaiser | ◇ | ◇ | — | — | — | — | ◇ |
Michael R. McDonnell | ◇ | ◇ | — | — | — | — | ◇ |
Scott R. Ward, Martha G. Aronson and Fred P. Lampropoulos served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- CONMED Corporation CNMD
- Globus Medical, Inc. GMED
- Haemonetics Corporation HAE
- ICU Medical, Inc. ICUI
- Inspire Medical Systems INSP
- Insulet Corporation PODD
- Integer Holdings Corporation ITGR
- Integra LifeSciences Holdings Corporation IART
- iRhythm Holdings, Inc. IRTC
- Lantheus Holdings, Inc. LNTH
- LivaNova Plc LIVN
- Masimo Corporation MASI
- Orthofix Medical, Inc. OFIX
- Penumbra, Inc. PEN
- QuidelOrtho Corporation QDEL
- Teleflex Incorporated TFX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 13, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 14, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 15, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 18, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 19, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 17, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 22, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 23, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 24, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 24, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | May 26, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Fred Lampropoulos (Former Chair of the Board, CEO and President), FY2025 total compensation $13,755,143 (base salary $1,890,000) [exec_comp, SEC accession 0000856982-26-000013, filed 2026-03-31]What this page does not include
Everything above is a fact Merit Medical Systems disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Merit Medical Systems sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
314 figures on this page: 303 cited to the filing that reported them, 11 calculated from figures it prints.
303 cited to the filing
11 calculated from the filing
Documents cited
- 0000856982-26-000030Item 5.07 Submission of Matters to a Vote of Security Holders.
- 0000856982-26-000013CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards · and 2 more sections
- 0000856982-25-000033Item 5.07 Submission of Matters to a Vote of Security Holders.
- 0000856982-25-000017Summary Compensation Table
- 0000856982-24-000050Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000856982-23-000026Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001558370-23-005437Summary Compensation Table
- 0000856982-22-000032Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000856982-21-000016Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000856982-20-000031Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000856982-19-000072Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000856982-18-000027Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000856982-17-000022
- 0000856982-16-000090Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Merit Medical Systems executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MMSI (accessed 2026).
Short form: data: Velarion
The Merit Medical Systems brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Merit Medical Systems and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Merit Medical Systems discloses
The companies named in MMSI's own disclosed peer group.
CONMED CorporationGlobus Medical, Inc.Haemonetics CorporationICU Medical, Inc.Inspire Medical SystemsInsulet CorporationInteger Holdings CorporationIntegra LifeSciences Holdings CorporationiRhythm Holdings, Inc.Lantheus Holdings, Inc.LivaNova PlcMasimo CorporationOrthofix Medical, Inc.Penumbra, Inc.QuidelOrtho CorporationTeleflex Incorporated
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}